Penumbra (PEN) Expected to Release Earnings on Wednesday

Penumbra (NYSE:PEN) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Penumbra to announce earnings of $1.20 per share and revenue of $401.41 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.88 earnings per share for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). The business had revenue of $390.05 million for the quarter, compared to analyst estimates of $389.64 million. During the same period in the prior year, the business posted $0.86 EPS. The business’s revenue for the quarter was up 14.9% on a year-over-year basis. On average, analysts expect Penumbra to post $4.96 EPS for the current fiscal year and $6.12 EPS for the next fiscal year.

Penumbra Price Performance

PEN stock opened at $317.35 on Wednesday. Penumbra has a 52-week low of $221.26 and a 52-week high of $362.41. The company’s 50-day simple moving average is $320.93 and its 200-day simple moving average is $327.37.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PEN shares. Evercore reaffirmed an “outperform” rating and issued a $320.00 price target on shares of Penumbra in a report on Monday, July 6th. Zacks Research upgraded Penumbra from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research note on Thursday, October 15th. Three analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $367.07.

About Penumbra

Penumbra, Inc is a medical device company that develops, manufactures and markets products used to treat patients with vascular conditions. Its technologies are primarily designed for minimally invasive procedures in the neurovascular and peripheral vascular markets, including the treatment of ischemic stroke, brain aneurysms and other vascular disorders.

The company’s product portfolio includes aspiration and mechanical thrombectomy systems for removing blood clots, embolization devices for blocking abnormal blood flow, and access and delivery products used during endovascular procedures.